Organogenesis Q1 Revenue Falls 58% to $36.3M, Loss Widens to $53.2M
Organogenesis reported Q1 net revenue of $36.3 million, down 58% from $86.7 million a year earlier, driven by a 63% drop in Advanced Wound Care sales to $29.5 million. The company posted a Q1 loss of $53.2 million, a $43.7 million adjusted net loss and $48.2 million adjusted EBITDA loss.
1. Revenue and Segment Performance
Net product revenue for Q1 2026 was $36.3 million, down 58% from $86.7 million in Q1 2025. Advanced Wound Care revenue fell 63% to $29.5 million while Surgical & Sports Medicine revenue remained flat at $6.8 million.
2. Expense and Loss Details
Gross profit declined to $10.5 million (29% margin) versus $63.0 million (73% margin) last year. Operating expenses were $106.1 million, R&D spending rose 42% to $15.2 million, and the company recorded a net loss of $53.2 million for the quarter.
3. Management Commentary and Outlook
Adjusted net loss widened to $43.7 million and adjusted EBITDA loss increased to $48.2 million. Management highlighted the upcoming ReNu BLA submission and stated confidence in driving significant market share gains in the second half of 2026.